Newsletter - November 5, 2020
Gilead’s PRV Highlights Another Financial Windfall Coming to Covid Vaccine Developers
The FDA approval of Remdesivir carried another incentive for Gilead granted to anyone developing a product to treat or prevent Covid, the Priority Review Voucher (PRV), which is potentially worth hundreds of millions of dollars. This is the second PRV for a Covid product and practically every Covid vaccine and treatment developer ...Read More
Industry Payments to Doctors Continue Despite the Sunshine Act Disclosures
Manufacturers paying prescribers to encourage preferred prescriptions is an unethical practice barred by most codes of ethics since it is effectively bribing physicians to influence their medical decisions. The Sunshine Act, 2010, requires manufacturers to disclose all payments made to physicians in any form with an intent to discourage such practice....Read More
Gilead’s PRV Highlights Another Financial Windfall Coming to Covid Vaccine Developers
The FDA approval of Remdesivir carried another incentive for Gilead granted to anyone developing a product to treat or prevent Covid, the Priority Review Voucher (PRV), which is potentially worth hundreds of millions of dollars. This is the second PRV for a Covid product and practically every Covid vaccine and treatment developer ...Read More
Industry Payments to Doctors Continue Despite the Sunshine Act Disclosures
Manufacturers paying prescribers to encourage preferred prescriptions is an unethical practice barred by most codes of ethics since it is effectively bribing physicians to influence their medical decisions. The Sunshine Act, 2010, requires manufacturers to disclose all payments made to physicians in any form with an intent to discourage such practice....Read More
